Loading...
Loading...
IMAB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 90.6M |
| Operating I/L | -90.6M |
| Other Income/Expense | 20.6M |
| Interest Income | 0.0M |
| Pretax | -70.0M |
| Income Tax Expense | -90.8M |
| Net Income/Loss | 20.8M |
I-Mab is a clinical stage biopharmaceutical company specializing in the discovery, development, and commercialization of biologics for the treatment of cancer and autoimmune disorders. The company's product pipeline includes a range of innovative therapies such as Felzartamab, Eftansomatropin alfa, TJ107, Lemzoparlimab, Enoblituzumab, Efineptakin, TJ210, Plonmarlimab, Uliledlimab, TJ-L14B, TJ-CD4B, TJ-L1IF, and TJ-C64B, targeting various indications in oncology and immunotherapy. I-Mab generates revenue through strategic collaborations with industry leaders such as AbbVie, Sinopharm Group, Kalbe Genexine Biologics, and Roche Diagnostics, as well as through the advancement of its product candidates through clinical trials and potential commercialization.
